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carotid artery intima-media thickness (CCA-IMT) and the
ankle-brachial index (ABI) were separately associated with
outcome after vascular surgery. Aim of the study was to
evaluate if these risk markers have an added predictive value
even on top of the RCR index.
Methods: A total of 647 patients with hs-CRP, CCA-
IMT and ABI assessment prior to surgery were included.
The primary endpoint was a composite of cardiac death and
non-fatal myocardial infarction.
Results: Based on multivariate hazard ratios (HRs), a
baseline hs-CRP6.5 mg/l was not predictive of a 30-day
cardiac event, in contrast with a CCA-IMT1.25mm and
an ABI0.91. However, all three risk markers had a signif-
icant association with long-term adverse outcome (Table).
Hazard ratios (HR) and odds ratios (OR) for cardiac
events after vascular surgery
30-day events HR 95% CI p-value
Cumulative
2
Revised cardiac risk
index 1.65 1.39-1.95 0.001 98.9
hs-CRP 6.5mg/l 1.10 0.82-1.49 0.521 99.3
CCA-IMT 1.25 1.44 1.07-1.94 0.016 105.1
ABI 0.90 2.05 1.53-2.74 0.001 125.2
Long-term events OR 95% CI p-value
Cumulative
2
Revised cardiac risk
index 1.69 1.45-1.98 0.001 152.4
hs-CRP 6.5mg/l 1.53 1.17-2.00 0.002 163.8
CCA-IMT 1.25 2.40 1.84-3.12 0.001 176.5
ABI 0.90 2.21 1.69-2.89 0.001 209.6
Multivariate analysis corrected for gender, age, hypertension, hypercholes-
terolemia, smoking and chronic obstructive pulmonary disease.
Conclusions:The current results show that combining
risk markers with risk factors as embedded in cardiac risk
indices can improve perioperative and long-term risk pre-
diction in vascular surgery patients. These additions to risk
prediction models should be investigated in other
populations.
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Objectives: To determine the viability, safety, and ef-
ficacy of various forms of atherectomy devices over a 5 year
period in the treatment of lower extremity arterial occlusive
disease. In addition, to determine if EPD use confers any
benefit with regards to distal embolization during the
atherectomy procedure.
Methods: Retrospective review of 150 limbs in 148
patients treated with atherectomy at a single institution
over a 5 year period. The atherectomy devices included
laser, rotational, and orbital atherectomy. Patient charac-
teristics, type of device used, success of delivery of atherec-
tomy device to target lesion, reconstruction techniques,
rate and type of complications, and subsequent procedures
were all examined. The use of EPD’s in atherectomy pro-
cedures were also examined with regard to the rate of distal
embolization.
Results:Median age of patients was 64.80% were male.
Successful delivery of atherectomy device to target lesion
was 93.3% (n140). The limb level of atherectomy inter-
vention was the superficial femoral artery in 60.7% (n91).
Median length of vessel treated was 12 cm. Majority of
reconstruction following atherectomy was balloon angio-
plasty alone in 63.3% (n95). Reconstruction success was
86.7% Vessel rupture or extravasation was seen in 13.3%.
78% of limbs did not require any further intervention. Rate
of major amputation after atherectomy was 9.3%. 26.7% of
limbs (n40) received an EPD prior to atherectomy, while
73.3% (n110) did not. The rate of distal embolization
was 12.5% in the EPD group and 15.5% in the non-EPD
group (p0.65, NS).
Conclusions: Atherectomy is a safe, viable, and effec-
tive method of intervention for lower extremity arterial
occlusive disease. The majority of patients required angio-
plasty alone as reconstruction after atherectomy. Subse-
quent rates of futher intervention or amputations were low.
In the embolic protection substudy, there was no signifi-
cant difference in the rate of distal embolization between
patients treated with or without an EPD.
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Objectives: To identify the impact of lower extremity
revascularization or amputation on 30-day mortality in
patients with preoperative do not resuscitate orders
documented.
Methods: Patients were identified from the 2005-
2008 ACS NSQIP datafile using CPT codes. Group-wise
comparisons based on DNR status were performed using
t-tests and 2. Associations between preoperative DNR
status, operative management (categorically evaluated as
revascularization versus amputation), and mortality were
evaluated using logistic regression.
Results: 15,541 operations were identified, of which
9417 were revascularizations and 6,124 were major ampu-
tations. 526 patients were DNR (1.1% of revasculariza-
tions; 6.8% of amputations. DNR patients were older and
had a greater prevalence of preoperative comorbid condi-
tions and abnormal laboratory data. Perioperative mortality
was 22.2% for DNR versus 5% for non-DNR patients
[univariate OR (95% CI) for DNR status: 5.4 (4.4-6.6);
P0.0001]. Multivariable modeling adjusting for preoper-
ative differences in demographic, comorbidity, and labora-
tory data revealed an interaction between DNR status and
procedural management (P0.0013). DNR status was as-
sociated with increased mortality risk following both revas-
cularization [Estimated(OR)(95% CI):4.9 (2.9-8.3)] and
amputation [Estimated (OR)(95% CI):1.9 (1.4-2.5)].
Conclusions: DNR patients are at increased risk for
perioperative mortality following both lower extremity am-
putation and revascularization, and this association be-
tween DNR status and mortality persists after adjusting for
differences in other risk factors. The differential effect on
mortality risk based on procedural management implies
greater risk for DNR patients undergoing revasculariza-
tion, but may reflect the influence of DNR status on
procedure selection given greater prevalence of DNR status
among these patients. DNR status should be considered
during preoperative risk assessment and may inform preop-
erative counseling and decision making.
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Objectives: To evaluate the safety and efficacy of trans-
plantation of purified peripheral blood CD34 cells in
treatment of no-option critical limb ischemia (NOCLI).
Methods: From May 2009 to Nov. 2010, 15 NOCLI
cases were included, 11 with thromboangitis, 2 atheroscle-
rosis obliterans, and 2 vasculitis, mean age 4415years.
G-CSF was subcutaneously injected for 5 days before
apheresis. CD34 cells were isolated with CliniMACS
system, and then intramuscularly injected into calf and foot.
Results: Technical success was achieved in all cases.
Major amputation was performed in 2 cases postopera-
tively, and the salvage rate was 87%. The mean number of
transplanted cells was (7.844.17) 105/kg. The fol-
low-up was accomplished in all cases, ranging from 1-19
months (mean 85months). One month after transplanta-
tion, the rest pain was obviously relieved in 11 cases, and
theWong-Baker FACES pain rating scale score significantly
decreased from 72 to 11, P0.0000. At 6 months, the
pain-free walking distance on treadmill measured in 8 eli-
gible cases was significantly improved from 3.03.0 min to
17.910.6 min (P0.001); the ankle-brachial index in-
creased from 0.450.22 to 0.690.13 ( P0.007); trans-
cutaneous partial oxygen pressure rose from 2912mmHg
to 579mmHg (P0.0002). Of 9 cases with the foot
ulcer, it was healed in 6 patients at 43months and appar-
ently shrank in 3. No serious complications were observed
either perioperatively or during the follow-up.
Conclusions: Transplantation of purified peripheral
blood CD34 cells appeared to be safe and effective in
treatment of NOCLI, and mid-to-long-term results is
pending further investigation.
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Objectives: Treatment options for aorto-ilac occlusive
disease (AIOD) include open and endovascular treatment.
We performed a meta-analysis of studies reporting the
treatment outcomes for AIOD.
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